ERBB2 and ductal breast carcinoma in situ: A retrospective analysis, performed on available tissue samples within the prospective UK/ANZ DCIS Randomized Trial, is the only large-scale study to date which performed HER2 IHC on a patient cohort with random allocation to adjuvant radiotherapy [12].